VIZAMYL

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Japan, Lithuania, Poland, Singapore, Spain, Turkey.

Active ingredients

The drug VIZAMYL contains one active pharmaceutical ingredient (API):

1	Flutemetamol ¹⁸F UNII L49M066S0O - FLUTEMETAMOL F-18
	Flutemetamol ¹⁸F binds to β-amyloid neuritic plaques in the brain. It is a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. VIZAMYL should be used in conjunction with a clinical evaluation.
	Read more about Flutemetamol ¹⁸F

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VIZAMYL Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V09AX04		V Various → V09 Diagnostic radiopharmaceuticals → V09A Central nervous system → V09AX Other central nervous system diagnostic radiopharmaceuticals
Discover more medicines within V09AX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1662588, 1662599
ES	Centro de información online de medicamentos de la AEMPS	114941002
FR	Base de données publique des médicaments	67652999
IT	Agenzia del Farmaco	043562014, 043562026
JP	医薬品医療機器総合機構	43004A4A1028
LT	Valstybinė vaistų kontrolės tarnyba	1073834, 1073835
PL	Rejestru Produktów Leczniczych	100326514
SG	Health Sciences Authority	15441P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699360730355
US	FDA, National Drug Code	17156-067